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INTRODUCTION
Cancer is a disease of complex etiology and
multistep progression, manipulating the
regular routes to homeostasis. Any devi-
ation from homeostasis alerts the innate
immune system and provokes inflamma-
tion. Inflammation is generated by the sig-
naling cascades launched by the pattern
recognition receptors (PRRs), the germ-
line encoded molecules dedicated to sense
pathogen, or danger-associated molecu-
lar patterns (PAMPs or DAMPs) in case
of pathogen/foreign matter invasion and
intrinsic disturbances, respectively (1–3).
Through inflammation, PRRs eliminate
stress signals and re-establish homeosta-
sis in the body, via drawing the required
cellular machinery to the inflammatory
sites. However, the same lympho-reticular
infiltrate has been linked with incidence
of cancer at the site of chronic inflam-
mation, since 1863, by Rudolf Virchow
(4). From 1990s vast amount of literature
has accumulated associating soluble and
cellular factors of innate immune system
with prevalence and progression of can-
cer. Furthermore, in the past decade, several
pathogens have been linked with cancer as
well [Ref. (5, 6) and references therein].
Fascinatingly, it is remarkable how
the tightly regulated sensory system
for stress removal and maintenance of
homeostasis functions anomalously and




All PRR-dependent pathways activate a
particular set of transcription factors to
generate appropriate responses. The same
factors govern cellular proliferation, apop-
tosis, tissue remodeling, or angiogenesis,
and exhibit a perturbed activity during
cancer. One such key protein is nuclear
factor κB (NFκB); up-regulation of which
leads to production of pro-inflammatory
cytokines. Additionally, it induces anti-
apoptotic proteins like Bcl2 or inhibitors
of apoptotic proteins (IAPs) and angio-
genic proteins, such as angiopoietin or vas-
cular endothelial growth factor (VEGF).
NFκB also induces nitrous oxide synthase-
2 (NOS-2), thus producing nitrous oxide
(NO) in the immune cells, which along
with reactive oxygen species (ROS) erad-
icates infected cells by lipid per-oxidation
and DNA damage (10–14). Conversely,
genomic instability and free radicals thus
produced act as DAMPs, leading to sensi-
tization of neighboring PRRs and further
immune activation, for instance, the DNA
fragments released can activate local DNA
sensors, resulting in production of Type
I IFN by DAI-TBK1, and activate KRAS
pathway of cellular proliferation via TBK1-
Sec5 complex, which leads to further acti-
vation of NFκB and production of anti-
apoptotic proteins (15). That is, detouring
regular anti-cancer pathway toward prolif-
eration. Also, RONS induce DNA methy-
lases, which lead to methylation and silenc-
ing of tumor suppressor and DNA damage
repair genes (2, 16–18).
Another pathway crucial in immu-
nity and cancer is the Janus kinases
(JAK)-signal transducers and activators
of transcription (STAT) pathway. Trig-
gered primarily by interferons and some
other mediators, this pathway stimu-
lates various proliferative genes, such
as IL-6-mediated induction of myc and
CyclinD1/D2 through JAK; also TNFα-
mediated up-regulation of STAT-3 leading
to activation of Ras-mitogen activated pro-
tein kinase (MAPK) pathway, which leads
to the expression of transcription factor
activating protein (AP)-1, and epidermal
growth factor (EGFs) along with eukary-
otic initiation factor (eIF)-4. AP-1 couples
with NFκB, inducing matrix metallopro-
teinase (MMP)-9, a protein involved in
tissue remodeling required during angio-
genesis (19). Thus, the pro-inflammatory
signal culminates in the production of
proteins aiding tumor survival, prolifera-
tion, and development of tumor-associated
vasculature (18).
Furthermore, NFκB is also involved in
the expression of NLRP3, which assembles
with apoptosis-associated speck-like pro-
tein containing a CARD (ASC) caspase-
1 to form multi-protein complexes, the
inflammasomes, and responds to DAMPs,
especially nucleotides released from dam-
aged or necrotic tissue (due to cyto-
toxicity of free radicals) (20). Likewise,
absent in myeloma (AIM)-2 inflamma-
somes also organize in response to the
formation of DNA adducts (DNA and
cytosolic protein HMGB-1) from the
dying tissue (21). These assemblies lead
to activation of IL-1β–IL-1βR pair; a
system found commonly over-activated
in many cancers (2, 22). Additionally,
NFκB also generates cyclo-oxygenase-2
(COX-2) enzyme, which converts arachi-
donic acid into prostaglandin-E2 (PGE-
2), one of the dual (pro-inflammatory
and/or anti-inflammatory) mediators of
immune response. PGE-2 enhances T-
cell activation and represses B-cell activ-
ity (23, 24). Another common enzyme,
activation-induced deaminase (AID), also
induced by NFκB, involved in somatic
hypermutation and class switch recombi-
nation in B-cells, causes genome insta-
bility and releases additional DAMPs
into the microenvironment (25). Thus,
the immune mediators produced for
protection can divert inflammation toward
pro-tumor facet (26).
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A set of pro-inflammatory cytokines
consisting of TNF-α and IL-1 and 6 is
essentially tumor directing. TNF-α pro-
motes tumor initiation and DNA damage.
It also up-regulates hypoxia-inducible fac-
tor (HIF)-1α (attributed to the increas-
ingly low oxygen levels due to multiply-
ing cells) aiding in angiogenesis (27). IL-
1β aids in tumor invasiveness and adhe-
sion required during metastasis to new
sites. IL-1α, the membrane bound form,
induces IL-1 expression, associated with
tissue damage, compensatory cell prolifera-
tion, and activation of JAK-STAT pathway,
as seen in hepatocellular carcinomas and
colitis-associated cancers (22, 28).
Cigarette smoking has long been asso-
ciated with incidence of cancer. Cigarette
smoke contains numerous compounds
with known cytotoxicity, mutagenicity, and
carcinogenicity, most of which are particu-
late. Stable ROS present in the smoke dam-
age DNA and cause lipid per-oxidation,
sensitizing the PRRs present from the buc-
cal cavity to lungs leading to increased IL-8
and TNF-α (11). In addition, both, NFκB
and AP-1 are up-regulated exaggerating the
pro-inflammatory signal, at the same time
homeostatic activity of both is reduced,
compensating normal immune response.
Such a response coupled with prolonged
exposure can spontaneously lead to cel-
lular transformations and their expan-
sion (29, 30).
ROLE OF CELLULAR COMPONENTS OF
INNATE IMMUNITY IN CANCER
PROGRESSION
Specialized cells of the immune system are
equipped with PRRs, and are responsible
for clearance of diseased/damaged cells.
Pro-inflammatory cytokines draw these
cells toward the inflammatory site and
direct them for removal of pathogens, par-
ticulates, or immune debris. These pop-
ulations recede as the signal resolves.
Since Virchow proposed their role at the
site of chronic inflammation and can-
cer, a number of cellular populations and
their effector responses have been ascer-
tained for the same. In cases of pro-
longed exposure to PAMPs/DAMPs, infil-
trating cells fail to withdraw and dif-
ferentiate into M2 macrophages, iden-
tified as tumor-associated macrophages
(TAMs), an integral population programed
for tissue remodeling and tumor progres-
sion. Upon activation of their PRRs, TAMs
promote various properties of cancer by
releasing a range of inflammatory and
angiogenic bio-chemicals. These cells stim-
ulate proliferation of stromal tissue and
macrophages by growth factors such as
platelet-derived growth factor (PDGF) and
colony stimulating factor (CSF)-1 respec-
tively (31). Moreover, they organize a route
to metastasis by digesting the substratum,
basal lamina and release inactive growth
factors via, MMPs. In addition, they assist
in cellular movements by releasing cell
adhesion molecules such as intercellular
adhesion molecule (ICAM)-1 (32–34).
Another such population, the NK
cells meant to carry out cytotoxic clear-
ance of all the cells which do not
express human leukocyte antigen (HLA)
A/B/C and thus fail to activate the
membrane-expressed inhibitory receptors
(NKp30/44/46). NK cells are also respon-
sible for killing any cell, irrespective
of HLA tag, which presents them with
stress/abnormality/tumor-associated anti-
gens, via, activating receptor (NKG2D).
In addition, they also participate in
antibody-dependent cell-mediated cyto-
toxicity (ADCC), on cells tagged through
FCRγIII (35, 36). A number of cytokines
activate NK cells and turn them into
lymphokine-activated killers, causing them
to display their killing property at the site
of recruitment (37). Tumor cells escape NK
cells by blocking the activating receptor.
Also, even if recruited, NK cells can only
bring about killing of the outer cells in a
solid tumor (38, 39). Furthermore, a reduc-
tion in NK cell cytotoxic function as well
as NK cell dependent tumor surveillance
is evident as a tumor directing effect of
cigarette smoke (29, 30).
Another newly characterized popula-
tion of cells called myeloid-derived sup-
pressor cells (MDSCs) are recruited by
inflammatory mediators, which inhibit
the anti-tumor responses and release
pro-tumor molecules, like, NOS-2 and
TGF-β. Arginase-1 and indolamine-2,3-
dioxygenase produced by MDSCs are
involved in silencing the anti-tumor
immunity by reducing Th1 activiza-
tion (40, 41).
Soluble and cellular factors work
in union. Cellular proliferation at an
enhanced rate at tumor sites gives rise
to hypoxia, low concentration of oxy-
gen that stabilizes HIF-1α, which activates
NFκB to secrete an angiogenic protein,
VEGF and also induces expression of IL-
12 and TNF-α. These mediators collec-
tively induce STAT-3 production that up-
regulates PGE-2 which further recruits NK
cells and their cytotoxic function releases
DAMPs in vicinity attracting TAMs which
aid in shaping neo-vasculature and cre-
ating area for growing cell mass. Dereg-
ulation of Th1 responses by PGE-2 and
MDSC/TAMs creates an imbalance (42–
44). HIF-1α which causes glycolytic envi-
ronment, such conditions may tip the bal-
ance into a state when IL-12 production
is replaced by IL-23, that is, a shift from
anti-tumor to pro-tumor (45, 46). In this
manner, the PRR triggered pathways to
eliminate PAMPs/DAMPs, are rerouted in
a manner that leads to exaggeration of
the initial signal causing chronic inflam-
mation; moreover eliciting other pathways
concluding in tumor growth and metasta-
sis (1, 47, 48).
REGULATORY MECHANISMS AND
PROGRESSION OF CANCER
To maintain homeostasis in the body, all
cellular processes, including PRR generated
immune responses are regulated by various
mechanisms. This control is exercised at
various levels. At transcriptional level cer-
tain cytokines can inhibit transcription fac-
tors, such as IL-4/13 which hinder NFκB.
Alternatively; some cytokines directly
inhibit other cytokines at protein level,
such as inhibition of TNF-α by IL-10. At
post-transcriptional level microRNAs play
a crucial role by either resolving inflamma-
tion or potentiating pro-tumor effects of
cytokines (18). For instance, TNF-α/IL-1β
induced mir-146a inhibits IRAK/TRAF6,
that is, the downstream signaling of
TLR pathway, thus resolving inflam-
mation (23). In contrast IL-6 induced
mir-21 targets tumor suppressor genes,
such as phosphatase and tensin homolog
(PTEN), programed cell death (PDCD)-4,
and others, thereby hampering the anti-
tumor effects (49–52). Another microRNA
found commonly up-regulated in can-
cer, miR-155, induces NOS-2 and inhibits
apoptosis by down-regulating TP53INP1
(a downstream molecule of p53 signaling)
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FIGURE 1 | Role of PRRs in maintenance of homeostasis and cancer
development. Exposure to any of the various stress stimuli leads to
activation of immune system through PRRs ( ) which results in expansion
of a variety of cellular populations and production of numerous cytokines
( ). A precise sensitive balance at the inflammatory and regulatory front
eliminates and reinstates homeostasis within the host. However, under
certain circumstances, the precise balance is altered due to
aberrant/exaggerated inflammation or failure of regulatory mechanisms to
restrict them. Such imbalance results in accumulation of cells and
chemicals that deregulate the proliferative pathways; induce angiogenesis
and damage the extracellular matrix, thus aiding in origin and/or
progression of cancers.
(53). Thus, a slight imbalance in the pro-
inflammatory and anti-inflammatory sig-
nals can shift the equilibrium toward onco-
genic transformations (18).
Pattern recognition receptor elicited sig-
naling cascades induce synthesis of sev-
eral zinc-finger proteins that help in
regulating the inflammatory signals. For
example, ZC3H12a/c and Zfp36 proteins
degrade the cellular mRNA coding for pro-
inflammatory cytokines; while ZAP pro-
teins directly degrade the viral RNA, to
be precise, the PAMP itself (54, 55). Thus,
these proteins degrade the PAMPs or sig-
nal generated by them to curb inflam-
mation. In addition, certain PRRs them-
selves restrain the downstream signaling
such as inhibition of IPS-1, adaptor mole-
cule of RLR, by NLRX-1. Mutations within
these genes or their regulatory elements
or imbalance at cellular level can skew
the balance toward tumorigenesis (6, 55)
(Figure 1).
NEW FACET IN THE FIELD
A relatively new but noteworthy field
in analyzing cancer biology is polymor-
phisms. Single nucleotide polymorphisms
(SNPs) are single base changes in the
DNA, which may produce totally dras-
tic effects on the structure and function
of the encoded molecules. PRRs and the
associated machinery, such as the adap-
tors or receptors are also susceptible to
such polymorphisms and many such SNPs
have been reported. SNPs could promote
the anti-tumor effect if they prevent the
PRR cascade from commencing, or sup-
port the pro-tumor effect, if they cause
spontaneous induction of signaling with-
out any stimulus. The cytoplasmic domains
of the PRRs and cytokine receptors are
of prime importance in this context as
they form the docking site for progression
of inflammatory response. Many polymor-
phisms have been identified to be asso-
ciated with cancers of various origins.
Mostly CLRs and RLRs have been asso-
ciated with sensing PAMPs of oncogenic
origin, and polymorphisms in their genes
have been correlated with cancers of meso-
derm, endoderm, and also ectoderm ori-
gin. Also several genes and mutations
have been correlated with cigarette smoke
in association with cancers (56). Still, a
rather comprehensive endeavor would be
required to establish the integral role of
these SNPs at the molecular level to outline
their part in incidences and progression
of cancers [Ref. (6) and references therein,
Ref. (56)].
CONCLUSION
Recognition of pathogen/stress is one
of the essential processes of the host.
Tumor cells are in fact, abnormal cells
which are steadily eliminated through
PRR-mediated pathways. However, hyper
or anomalous behavior of same path-
ways can divert the protective route
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toward malignancy, by contributing to
abnormal proliferation, angiogenesis, or
modifying tissue architecture. The ori-
gin of anomalous behavior maybe exter-
nal and internal, such as pathogen/foreign
insults tissue damage/necrosis or muta-
tions and polymorphisms in vital sig-
naling components, respectively. Unfold-
ing the root of these irregularities and
malfunctions shall help in better under-
standing of the disease and thus, cre-
ate new and personalized prospects for
treatment.
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